Femasys Inc. (FEMY)
NCM · Healthcare · Medical Instruments & Supplies
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Femasys Inc.
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 409K | 729K | 813K | 425K |
| Gross Profit | 251K | 436K | 510K | 266K |
| Operating Income | -3.9M | -3.7M | -4.6M | -4.2M |
| Net Income | -4.6M | -4.2M | -4.0M | 846K |
| Diluted EPS | $-3.20 | $-2.00 | $nan | $0.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.2M | 1.1M | 1.6M | 2.3M |
| Gross Profit | 764K | 692K | 1.1M | 1.4M |
| Operating Income | -11.6M | -14.5M | -17.8M | -17.6M |
| Net Income | -11.4M | -14.2M | -18.8M | -18.6M |
| Diluted EPS | $-19.20 | $-18.60 | $-17.00 | $-9.40 |